PharmaEngine, Inc.

Total Valuation

PharmaEngine, Inc. carries a market capitalization of 9.14B, placing it among publicly traded companies globally. Its enterprise value stands at 5.55B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

PharmaEngine, Inc. currently has 143.68M shares outstanding.

Valuation Ratios

PharmaEngine, Inc. trades at a trailing price-to-earnings ratio of 26.36. The price-to-sales ratio is 11.21, and the price-to-book ratio stands at 3.48.

Enterprise Valuation

On an enterprise value basis, PharmaEngine, Inc. trades at an EV/EBITDA multiple of 13.03 and an EV/FCF ratio of 3.21. The EV/Sales ratio of 6.08 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 13.03 provides insight into valuation relative to core operating earnings.

Financial Position

PharmaEngine, Inc. maintains a current ratio of 27.17, meaning it holds 27.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.86, indicating moderate leverage, while an interest coverage ratio of 3,061.02 demonstrates limited ability to service its debt obligations.

Financial Efficiency

PharmaEngine, Inc. posts a return on equity of 11.88 and a return on invested capital of 6.03.

Taxes

Over the trailing twelve months, PharmaEngine, Inc. has paid 121.65M in income taxes, reflecting an effective tax rate of 23.89.

Stock Price Statistics

PharmaEngine, Inc.'s stock has declined approximately -15.31292% over the past 52 weeks. The 50-day moving average sits at 56.62, while the 200-day moving average is 64.07.

Income Statement

Over the trailing twelve months, PharmaEngine, Inc. generated 911.42M in revenue and converted that into 387.64M in net income, yielding earnings per share of 2.67. EBITDA reached 425.48M, while operating income came in at 425.48M.

Balance Sheet

PharmaEngine, Inc. holds 4.72B in cash and equivalents against 42.12M in total debt, resulting in a net debt position of -1.58B. Total book value stands at 2.94B, with working capital of 4.90B providing operational flexibility.

Cash Flow

PharmaEngine, Inc. produced 1.73B in operating cash flow over the past twelve months. After subtracting -280,000.00 in capital expenditures, free cash flow totaled 1.73B - equivalent to 11.89 per share.

Margins

PharmaEngine, Inc. operates with a gross margin of 94.31, reflecting its pricing power and cost economics. The operating margin of 46.68 and net profit margin of 42.53 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

PharmaEngine, Inc.'s most recent stock split took place on July 26, 2017 with a 1000:1199 split ratio.

Scores

PharmaEngine, Inc. posts an Altman Z-Score of 29.67, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.